Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Posted by Francis Steltz on Aug 11th, 2026

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Get Free Report) has been given an average rating of “Moderate Buy” by the six ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $55.80.

Separately, Oppenheimer boosted their price objective on shares of Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th.

Get Our Latest Stock Analysis on PTHS

Insiders Place Their Bets

In related news, Director Todd C. Davis purchased 35,948 shares of Pelthos Therapeutics stock in a transaction that occurred on Thursday, June 11th. The stock was purchased at an average cost of $27.82 per share, with a total value of $1,000,073.36. Following the completion of the transaction, the director directly owned 75,834 shares in the company, valued at approximately $2,109,701.88. The trade was a 90.13% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 1,638 shares of company stock valued at $43,107 over the last three months. 12.70% of the stock is owned by insiders.

Institutional Trading of Pelthos Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Persistent Asset Partners Ltd grew its stake in Pelthos Therapeutics by 150.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock worth $186,000 after buying an additional 3,604 shares during the last quarter. Pale Fire Capital SE lifted its stake in Pelthos Therapeutics by 59.5% in the first quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after buying an additional 4,819 shares during the last quarter. Millennium Management LLC purchased a new stake in Pelthos Therapeutics in the fourth quarter valued at approximately $343,000. Geode Capital Management LLC boosted its holdings in shares of Pelthos Therapeutics by 31.9% in the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after acquiring an additional 3,295 shares during the period. Finally, Knott David M Jr grew its position in shares of Pelthos Therapeutics by 9.3% during the first quarter. Knott David M Jr now owns 21,073 shares of the company’s stock worth $443,000 after acquiring an additional 1,792 shares during the last quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.

Pelthos Therapeutics Trading Up 2.3%

NYSEAMERICAN:PTHS opened at $29.00 on Tuesday. Pelthos Therapeutics has a 1 year low of $16.50 and a 1 year high of $37.50. The stock has a market cap of $100.92 million, a P/E ratio of -1.41 and a beta of 3.10. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.86 and a current ratio of 2.79. The stock has a 50-day simple moving average of $27.27 and a 200-day simple moving average of $25.02.

Pelthos Therapeutics (NYSEAMERICAN:PTHS – Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share for the quarter. The firm had revenue of $10.91 million during the quarter. As a group, analysts anticipate that Pelthos Therapeutics will post -12.63 earnings per share for the current fiscal year.

Pelthos Therapeutics Company Profile

(Get Free Report)

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).